SlowBull
The Business Brief FRIDAY, 21 AUGUST 2026
← All stories
Markets

Moderna’s 177% Surge Has Investors Asking What Comes Next

1 source ·1 article ·7h ago

Moderna shares surged 177% after its melanoma vaccine, developed with Merck, outperformed an established therapy in a late-stage trial, triggering a massive short squeeze.

Covered by 1 outlet

Marketbeat 1

All coverage · 1 article

MarketBeat ·7h ago

Moderna’s 177% Surge Has Investors Asking What Comes Next

Moderna shares surged 177% after its melanoma vaccine, developed with Merck, outperformed an established therapy in a late-stage trial, triggering a massive short squeeze.